Glucocorticoids and the risk of osteoporosis

Expert Opinion on Drug Safety

Volumn 8, Issue 1, 2009, Pages 33-47

  Caplan, Liron ^a   Saag, Kenneth G ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Adverse effects; Glucocorticoids; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; CALCITONIN; CALCITRIOL; CALCIUM; CLODRONIC ACID; COLECALCIFEROL; ERGOCALCIFEROL; ESTROGEN; ETIDRONIC ACID; FLUORIDE; GLUCOCORTICOID; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISOLONE; PREDNISONE; RALOXIFENE; RISEDRONIC ACID; STRONTIUM; TESTOSTERONE; VITAMIN D; ZOLEDRONIC ACID;

APOPTOSIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DIET SUPPLEMENTATION; DRUG MECHANISM; DRUG MEGADOSE; EPIDEMIOLOGICAL DATA; FRACTURE; FRAGILITY FRACTURE; HEALTH CARE PERSONNEL; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MUSCLE ATROPHY; OBSERVATIONAL STUDY; OSTEOLYSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; REGISTRATION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SEMANTICS; TREATMENT INDICATION; VERTEBRA FRACTURE;

BONE DENSITY CONSERVATION AGENTS; FRACTURES, BONE; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 67649425767     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330802648194     Document Type: Review

References (148)

1. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001 ; 285 : 785-795 (Pubitemid 32167238)
2. Thorn GW, Forsham PH, Frawley TF, et al. The clinical usefulness of ACTH and cortisone. N Engl J Med 1950 ; 242 : 783-793
3. Thorn GW, Forsham PH, Frawley TF, et al. The clinical usefulness of ACTH and cortisone. N Engl J Med 1950 ; 242 : 824-834
4. Thorn GW, Forsham PH, Frawley TF, et al. The clinical usefulness of ACTH and cortisone. N Engl J Med 1950 ; 242 : 865-872
5. Steinbocker O, Berkowitz S, Carp S, et al. ACTH and cortisone as therapeutic agents in arthritis and some locomotor disorders. Bull NY Acad Med 1951 ; 27 : 560-576
6. Seeman E, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 2006 ; 354 : 2250 -61 • Discusses the basic pathophysiologic basis of osteoporosis, including the architectural properties of bone; explains the general mechanisms underlying anti-resorptive and anabolic therapies.
7. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007 ; 18 : 1319-1328 (Pubitemid 47389469)
8. Delany AM, Jeffrey JJ, Rydziel S, et al. Cortisol increases interstitial collagenase expression in osteoblasts by post-transcriptional mechanisms. J Biol Chem 1995 ; 270 : 26607-26612
9. Chang DJ, Ji C, Kim KK, et al. Reduction in transforming growth factor beta receptor I expression and transcription factor CBFa1 on bone cells by glucocorticoid. J Biol Chem 1998 ; 273 : 4892-4896 (Pubitemid 28108639)
10. Ohnaka K, Tanabe M, Kawate H, et al. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 2005 ; 329 : 177-181 (Pubitemid 40255437)
11. Horsch K, de Wet H, Schuurmans MM, et al. Mitogen-activated protein kinase phosphatase 1/dual specifi city phosphatase 1 mediates glucocorticoid inhibition of osteoblast proliferation. Mol Endocrinol 2007 ; 21 : 2929-2940 (Pubitemid 350225576)
12. Rubin J, Biskobing DM, Jadhav L, et al. Dexamethasone promotes expression of membrane-bound macrophage colony-stimulating factor in murine osteoblast-like cells. Endocrinology 1998 ; 139 : 1006-1012 (Pubitemid 28510117)
13. Sasaki N, Kusano E, Ando Y, et al. Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis. Bone 2002 ; 30 : 853-858 (Pubitemid 34616013)
14. Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999 ; 140 : 4382-4389 (Pubitemid 30666099)
15. Jia D, O'brien CA, Stewart SA, et al. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 2006 ; 147 : 5592-5599
16. Weinstein RS, Jilka RL, Parfi tt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998 ; 102 : 274-282 (Pubitemid 28335186)
17. O'brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004 ; 145 : 1835 -41 • The critical role of the osteocyte in glucocorticoid-induced osteoporosis is demonstrated in this interesting and well-executed series of experiments.
18. Lane NE, Yao W, Balooch M, et al. Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-defi cient mice. J Bone Miner Res 2006 ; 21 : 466 -76 • This study provides insight into the architectural characteristics that distinguish animal models of glucocorticoid-induced osteoporosis and post-menopausal osteoporosis. (Pubitemid 43306568)
19. Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002 ; 13 : 777 -87 • A large volume of data from observational reports is synthesized in this seminal work.
20. Dalle Carbonare L, Arlot ME, Chavassieux PM, et al. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 2001 ; 16 : 97-103 (Pubitemid 32046193)
21. Chappard D, Legrand E, Basle MF, et al. Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study. J Bone Miner Res 1996 ; 11 : 676-685 (Pubitemid 26123919)
22. Raisz LG. Prostaglandins and bone: physiology and pathophysiology. Osteoarthritis Cartilage 1999 ; 7 : 419-421 (Pubitemid 29331567)
23. Bonewald LF, Johnson ML. Osteocytes, mechanosensing and Wnt signaling. Bone 2008 ; 42 : 606-615
24. Canalis E, Rydziel S, Delany AM, et al. Insulin-like growth factors inhibit interstitial collagenase synthesis in bone cell cultures. Endocrinology 1995 ; 136 : 1348-1354
25. Delany AM, Durant D, Canalis E. Glucocorticoid suppression of IGF I transcription in osteoblasts. Mol Endocrinol 2001 ; 15 : 1781-1789 (Pubitemid 32939308)
26. Montecucco C, Caporali R, Caprotti P, et al. Sex hormones and bone metabolism in postmenopausal rheumatoid arthritis treated with two different glucocorticoids. J Rheumatol 1992 ; 19 : 1895-1900 (Pubitemid 23018520)
27. MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986 ; 104 : 648-651 (Pubitemid 16114558)
28. Sakakura M, Takebe K, Nakagawa S. Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects. J Clin Endocrinol Metab 1975 ; 40 : 774-779
29. Compston JE. Sex steroids and bone. Physiol Rev 2001 ; 81 : 419-447 (Pubitemid 32096180)
30. Morris HA, Need AG, O'loughlin PD, et al. Malabsorption of calcium in corticosteroid-induced osteoporosis. Calcif Tissue Int 1990 ; 46 : 305-308
31. Rubin MR, Bilezikian JP. Clinical review 151: the role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J Clin Endocrinol Metab 2002 ; 87 : 4033-4041
32. Canalis E, Bilezikian JP, Angeli A, Giustina A. Perspectives on glucocorticoid-induced osteoporosis. Bone 2004 ; 34 : 593-598 (Pubitemid 38393793)
33. Dardevet D, Sornet C, Savary I, et al. Glucocorticoid effects on insulin- and IGF-I-regulated muscle protein metabolism during aging. J Endocrinol 1998 ; 156 : 83-89 (Pubitemid 28049867)
34. Natsui K, Tanaka K, Suda M, et al. High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int 2006 ; 17 : 105-108 (Pubitemid 41798034)
35. Taaffe DR, Simonsick EM, Visser M, et al. Lower extremity physical performance and hip bone mineral density in elderly black and white men and women: cross-sectional associations in the Health ABC Study. J Gerontol A Biol Sci Med Sci 2003 ; 58 : M934 -42 (Pubitemid 37296688)
36. Sipila S, Heikkinen E, Cheng S, et al. Endogenous hormones, muscle strength, and risk of fall-related fractures in older women. J Gerontol A Biol Sci Med Sci 2006 ; 61 : 92-96 (Pubitemid 43227806)
37. Nguyen T, Sambrook P, Kelly P, et al. Prediction of osteoporotic fractures by postural instability and bone density. BMJ 1993 ; 307 : 1111-1115 (Pubitemid 23313207)
38. Laan RF, van Riel PL, van de Putte LB, et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 1993 ; 119 : 963-968
39. Van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003 ; 48 : 3224-3229 (Pubitemid 37409336)
40. Mudano A, Allison J, Hill J, et al. Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort. J Rheumatol 2001 ; 28 : 1298-1305 (Pubitemid 32510502)
41. Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006 ; 65 : 285-293 (Pubitemid 43268214)
42. Haugeberg G, Strand A, Kvien TK, Kirwan JR. Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial. Arch Intern Med 2005 ; 165 : 1293-1297 (Pubitemid 40989595)
43. Jordan KM, Cooper C. Epidemiology of osteoporosis. Best Pract Res Clin Rheumatol 2002 ; 16 : 795-806 (Pubitemid 35469029)
44. Guler-Yuksell M, Allaart CF, Breedveld FC, et al. Bone mineral density (BMD) measured by digital x-ray radiogrammetry (DXR) and dual energy x-ray absorptiometry (DEXA) in patients with recent onset rheumatoid arthritis (RA) after 1 year of treatment in the Best study [abstract]. Arthritis Rheum 2007 ; 56 (Suppl): S275
45. Walsh LJ, Wong CA, Pringle M, Tattersfi eld AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996 ; 313 : 344-346
46. Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids in the United Kingdom. QJM 2000 ; 93 : 105-111 (Pubitemid 30098773)
47. Caplan L, Wolfe F, Russell AS, Michaud K. Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol 2007 ; 34 : 696-705 (Pubitemid 46641373)
48. Lems WF. Pathophysiology of glucocorticoid-induced osteoporosis (GIOP) [slides 35-40]. Boston: ACR/ARHP Annual Scientifi c Meeting; 2007
49. Lodder MC, Lems WF, Kostense PJ, et al. Bone loss due to glucocorticoids: update of a systematic review of prospective studies in rheumatoid arthritis and other diseases [abstract]. Ann Rheum Dis 2003 ; 62 (Suppl 1): 94
50. Angeli A, Guglielmi G, Dovio A, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 2006 ; 39 : 253-259 (Pubitemid 43870263)
51. Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000 ; 15 : 993 -1000 • The relationship of various measures of glucocorticoid exposures to fractures is explored in the observational study based on the General Practice Research Database.
52. Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001 ; 345 : 941-947 (Pubitemid 34940809)
53. De Vries F, Bracke M, Leufkens HG, et al. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 2007 ; 56 : 208-214 (Pubitemid 46106193)
54. Naganathan V, Jones G, Nash P, et al. Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use. Arch Intern Med 2000 ; 160 : 2917-2922 (Pubitemid 32009048)
55. Peel NF, Moore DJ, Barrington NA, et al. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 1995 ; 54 : 801-806
56. Kumagai S, Kawano S, Atsumi T, et al. Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune diseases. J Rheumatol 2005 ; 32 : 863-869 (Pubitemid 40676497)
57. Kaji H, Tobimatsu T, Naito J, et al. Body composition and vertebral fracture risk in female patients treated with glucocorticoid. Osteoporos Int 2006 ; 17 : 627-633
58. Van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000 ; 39 : 1383-1389 (Pubitemid 32045866)
59. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. Calcif Tissue Int 2008 ; 82 : 249-257
60. Hermus AR, Smals AG, Swinkels LM, et al. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. J Clin Endocrinol Metab 1995 ; 80 : 2859-2865
61. Gafni RI, Mccarthy EF, Hatcher T, et al. Recovery from osteoporosis through skeletal growth: early bone mass acquisition has little effect on adult bone density. FASEB J 2002 ; 16 : 736-738
62. Porter RM. Examination of Glucocorticoid Treatment on Bone Marrow Stroma: Implications for Bone Disease and Applied Bone Regeneration [thesis]. Virginia Polytechnic Institute and State University; 2002
63. Mori S, Kou I, Sato H, et al. Association of genetic variations of genes encoding thrombospondin, type 1, domain-containing 4 and 7A with low bone mineral density in Japanese women with osteoporosis. J Hum Genet 2008 ; 53 : 694-697
64. Leclerc N, Luppen CA, Ho VV, et al. Gene expression profi ling of glucocorticoid-inhibited osteoblasts. J Mol Endocrinol 2004 ; 33 : 175-193 (Pubitemid 39206356)
65. Morrison NA, Qi JC, Tokita A, et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994 ; 367 : 284-287 (Pubitemid 24051146)
66. Sainz J, Van Tornout JM, Loro ML, et al. Vitamin D-receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent. N Engl J Med 1997 ; 337 : 77-82 (Pubitemid 27284392)
67. Ho YV, Briganti EM, Duan Y, et al. Polymorphism of the vitamin D receptor gene and corticosteroid-related osteoporosis. Osteoporos Int 1999 ; 9 : 134-138 (Pubitemid 29219074)
68. Gennari L, De Paola V, Merlotti D, et al. Steroid hormone receptor gene polymorphisms and osteoporosis: a pharmacogenomic review. Expert Opin Pharmacother 2007 ; 8 : 537-553 (Pubitemid 46547009)
69. Cooper MS, Blumsohn A, Goddard PE, et al. 11beta-hydroxysteroid dehydrogenase type 1 activity predicts the effects of glucocorticoids on bone. J Clin Endocrinol Metab 2003 ; 88 : 3874-3877 (Pubitemid 37034541)
70. Guidelines Working Group of The Royal College of Physicians, The Bone and Tooth Society of Great Britain, The National Osteoporosis Society. Glucocorticoid-induced osteoporosis: Guidelines for prevention and treatment. Royal College of Physicians of London; 2002 • This work thoroughly reviews the early evidence supporting various therapies for the prevention and treatment of GIO.
71. Abadie EC, Devogealer JP, Ringe JD, et al. Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science. Semin Arthritis Rheum 2005 ; 35 : 1-4 (Pubitemid 41111464)
72. Brody BA, Dickey N, Ellenberg SS, et al. Is the use of placebo controls ethically permissible in clinical trials of agents intended to reduce fractures in osteoporosis? J Bone Miner Res 2003 ; 18 : 1105-1109
73. Miller PD. Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data. Curr Med Res Opin 2008 ; 24 : 107-119 (Pubitemid 351160244)
74. Amin S, Lavalley MP, Simms RW, Felson DT. The comparative effi cacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 2002 ; 17 : 1512-1526 (Pubitemid 34803834)
75. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007 ; 357 : 2028-2039 (Pubitemid 350106710)
76. Kanis JA, Stevenson M, Mccloskey EV, et al. Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 2007 ; 11 :iii-iv, ix-xi, 1-231 (Pubitemid 46850492)
77. Osteoporosis. Geneva, Switzerland: Geneva Foundation for Medical Education and Research,2008. Available from: http://www.gfmer.ch/Guidelines/ Osteoporosis/Osteoporosis.htm [Last accessed 15 October 2008 ]
78. Adler RA, Hochberg MC. Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med 2003 ; 163 : 2619-2624 (Pubitemid 37464420)
79. Compston JE. Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis. Curr Rheumatol Rep 2007 ; 9 : 78-84 (Pubitemid 46806312)
80. Glucocorticoid-induced osteoporosis. Geneva, Switzerland: Geneva Foundation for Medical Education and Research, 2008. Available from: http:// www.gfmer.ch/Guidelines/Osteoporosis/ Glucocorticoid-induced-osteoporosis.htm [Last accessed 15 October 2008 ]
81. Nawata H, Soen S, Takayanagi R, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 2005 ; 23 : 105-109
82. Devogelaer JP, Goemaere S, Boonen S, et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 2006 ; 17 : 8-19 (Pubitemid 41798023)
83. Geusens PP, Lems WF, Verhaar HJ, et al. Review and evaluation of the Dutch guidelines for osteoporosis. J Eval Clin Pract 2006 ; 12 : 539-548 (Pubitemid 44427286)
84. Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001 ; 44 : 1496-1503
85. Ettinger B, Chidambaran P, Pressman A. Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs. Am J Manag Care 2001 ; 7 : 597-605 (Pubitemid 32551835)
86. Curtis JR, Westfall AO, Allison JJ, et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 2005 ; 52 : 2485-2494 (Pubitemid 41117436)
87. Kamen DL, Lane NE, Michaud K, Wolfe F. Increased Fracture and Osteoporosis (OP) Rates but Limited Prophylaxis in Rheumatoid Arthritis (RA) Patients [abstract]. Arthritis Rheum 2004 ; 50 (Suppl): 1803
88. Solomon DH, Katz JN, Jacobs JP, et al. Management of glucocorticoid- induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. Arthritis Rheum 2002 ; 46 : 3136-3142 (Pubitemid 35453521)
89. Feldstein AC, Elmer PJ, Nichols GA, Herson M. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int 2005 ; 16 : 2168-2174 (Pubitemid 41790940)
90. Duyvendak M, Naunton M, Atthobari J, et al. Corticosteroid-induced osteoporosis prevention: longitudinal practice patterns in The Netherlands 2001-2005. Osteoporos Int 2007 ; 18 : 1429-1433
91. Blalock SJ, Norton LL, Patel RA. Adherence to the American College of Rheumatology Guidelines for the Prevention and Treatment of Glucocorticoid- Induced Osteoporosis [abstract]. Arthritis Rheum 2004 ; 50 (Suppl): 1825
92. Elliott ME, Farrah RM, Binkley NC, et al. Management of glucocorticoid-induced osteoporosis in male veterans. Ann Pharmacother 2000 ; 34 : 1380-1384
93. Lazzari AA, Dussault PM, Young MM, et al. Chronic use of oral corticosteroids and compliance with ACR guidelines [abstract]. Arthritis Rheum 2003 ; 48 (Suppl): S462
94. Cline RR, Farley JF, Hansen RA, Schommer JC. Osteoporosis beliefs and antiresorptive medication use. Maturitas 2005 ; 50 : 196-208 (Pubitemid 40269903)
95. Howard WJ. A critical review of the role of targeted education for osteoporosis prevention. J Orthop Nurs 2001 ; 5 : 131-135 (Pubitemid 33668288)
96. Mauck KF, Cuddihy MT, Trousdale RT, et al. The decision to accept treatment for osteoporosis following hip fracture: exploring the woman's perspective using a stage-of-change model. Osteoporos Int 2002 ; 13 : 560-564 (Pubitemid 34790628)
97. Tussing L, Chapman-Novakofski K. Osteoporosis prevention education: behavior theories and calcium intake. J Am Diet Assoc 2005 ; 105 : 92-97 (Pubitemid 40075498)
98. Solomon DH, Katz JN, La Tourette AM, Coblyn JS. Multifaceted intervention to improve rheumatologists' management of glucocorticoid-induced osteoporosis: a randomized controlled trial. Arthritis Rheum 2004 ; 51 : 383-387 (Pubitemid 38725137)
99. Curtis JR, Westfall AO, Allison J, et al. Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trial. Arch Intern Med 2007 ; 167 : 591-596 (Pubitemid 46513229)
100. Guzman-clark JR, Fang MA, Sehl ME, et al. Barriers in the management of glucocorticoid-induced osteoporosis. Arthritis Rheum 2007 ; 57 : 140-146 (Pubitemid 46256736)
101. Buckley LM, Marquez M, Hudson JO, et al. Variations in physicians' judgments about corticosteroid induced osteoporosis by physician specialty. J Rheumatol 1998 ; 25 : 2195-2202 (Pubitemid 28505868)
102. Sedlak CA, Doheny MO, Estok PJ, Zeller RA. Tailored Interventions to Enhance Osteoporosis Prevention in Women. Orthop Nurs 2005 ; 24 : 270-276
103. Johnson SL, Petkov VI, Williams MI, et al. Improving osteoporosis management in patients with fractures. Osteoporos Int 2005 ; 16 : 1079-1085 (Pubitemid 41225094)
104. Harrington JT, Barash HL, Day S, Lease J. Redesigning the care of fragility fracture patients to improve osteoporosis management: a health care improvement project. Arthritis Rheum 2005 ; 53 : 198-204 (Pubitemid 40530159)
105. Cuddihy MT, Amadio PC, Melton LJ. Patient barriers to osteoporosis interventions after fracture. Mayo Clin Proc 2002 ; 77 : 875-876
106. Simonelli C, Killeen K, Mehle S, Swanson L. Barriers to osteoporosis identifi cation and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc 2002 ; 77 : 334-338 (Pubitemid 34260741)
107. Colon-Emeric C, Yballe L, Sloane R, et al. Expert physician recommendations and current practice patterns for evaluating and treating men with osteoporotic hip fracture. J Am Geriatr Soc 2000 ; 48 : 1261-1263 (Pubitemid 30769917)
108. Smith MD, Ross W, Ahern MJ. Missing a therapeutic window of opportunity: an audit of patients attending a tertiary teaching hospital with potentially osteoporotic hip and wrist fractures. J Rheumatol 2001 ; 28 : 2504-2508 (Pubitemid 33031983)
109. Juby AG, De Geus-Wenceslau CM. Evaluation of osteoporosis treatment in seniors after hip fracture. Osteoporos Int 2002 ; 13 : 205-210 (Pubitemid 34408186)
110. Kamel HK, Hussain MS, Tariq S, et al. Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture. Am J Med 2000 ; 109 : 326-328
111. Feldstein A, Elmer PJ, Orwoll E, et al. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med 2003 ; 163 : 2165-2172 (Pubitemid 37248781)
112. Compston J, Reid DM, Boisdron J, et al. Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporos Int 2008 ; 19 : 1247-1250
113. Cummings S, Mcclung MR, Christiansen C, et al. A phase III study of the effects of Denosumab on vertebral, nonvertebral, and hip fracture in women with osteoporosis: results from the FREEDOM trial [abstract #1286]. ASBMR 30th Annual Meeting in Montreal, Quebec, Canada, September 11-16, 23 edition; 2008
114. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006 ; 354 : 821-831 (Pubitemid 43290920)
115. Padhi D, Stouch B, Jang G, et al. Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women [abstract #1129]. ASBMR 29th Annual Meeting in Honolulu, Hawaii, USA, September 15-19, 22 edition; 2007. p. S37
116. Fully human anti-DKK1 antibodies increase bone formation and resolve osteopenia in mouse models of estrogen-defi ciency induced bone loss [abstract #1214]. ASBMR 30th Annual Meeting in Montreal, Quebec, Canada, September 11-16, 23 edition; 2008
117. McClung M, Bone H, Cosman F, et al. A randomized, double-blind, placebo-controlled study of Odanacatib (MK-822) in the treatment of postmenopausal women with low bone mineral density: 24-month results [abstract#1291]. ASBMR 30th Annual Meeting in Montreal, Quebec, Canada, September 11-16, 23 edition; 2008
118. Dexter PR, Perkins S, Overhage JM, et al. A computerized reminder system to increase the use of preventive care for hospitalized patients. N Engl J Med 2001 ; 345 : 965-970 (Pubitemid 34940813)
119. Shea S, Dumouchel W, Bahamonde L. A meta-analysis of 16 randomized controlled trials to evaluate computer-based clinical reminder systems for preventive care in the ambulatory setting. J Am Med Inform Assoc 1996 ; 3 : 399-409 (Pubitemid 126445041)
120. Hunt DL, Haynes RB, Hanna SE, Smith K. Effects of computer-based clinical decision support systems on physician performance and patient outcomes: a systematic review. JAMA 1998 ; 280 : 1339-1346 (Pubitemid 28473723)
121. Shekelle PG, Morton SC, Keeler EB. Costs and benefi ts of health information technology. Evid Rep Technol Assess 2006 ; 132 : 1-71
122. Chaudhry B, Wang J, Wu S, et al. Systematic review: impact of health information technology on quality, effi ciency, and costs of medical care. Ann Intern Med 2006 ; 144 : 742-752 (Pubitemid 46780634)
123. Bennett JW, Glasziou PP. Computerised reminders and feedback in medication management: a systematic review of randomised controlled trials. Med J Aust 2003 ; 178 : 217-222 (Pubitemid 36329215)
124. Dovio A, Perazzolo L, Saba L, et al. High-dose glucocorticoids increase serum levels of soluble IL-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorption. Eur J Endocrinol 2006 ; 154 : 745-751 (Pubitemid 43810862)
125. Nuttall ME, Gimble JM. Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharmacol 2004 ; 4 : 290-294 (Pubitemid 38585315)
126. Kim HJ, Zhao H, Kitaura H, et al. Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 2006 ; 116 : 2152-2160 (Pubitemid 44162324)
127. Canalis E. Effect of glucocorticoids on type I collagen synthesis, alkaline phosphatase activity, and deoxyribonucleic acid content in cultured rat calvariae. Endocrinology 1983 ; 112 : 931-939
128. Advani S, Lafrancis D, Bogdanovic E, et al. Dexamethasone suppresses in vivo levels of bone collagen synthesis in neonatal mice. Bone 1997 ; 20 : 41-46 (Pubitemid 27046018)
129. Liu Y, Porta A, Peng X, et al. Prevention of glucocorticoid-induced apoptosis in osteocytes and osteoblasts by calbindin-D28k. J Bone Miner Res 2004 ; 19 : 479-490 (Pubitemid 38787404)
130. Espallargues M, Sampietro-colom L, Estrada MD, et al. Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements: a systematic review of the literature. Osteoporos Int 2001 ; 12 : 811-822 (Pubitemid 33086268)
131. Siris ES, Miller PD, Barrett-connor E, et al. Identifi cation and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001 ; 286 : 2815-2822 (Pubitemid 33126923)
132. Van Staa TP, Geusens P, Pols HA, et al. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 2005 ; 98 : 191-198 (Pubitemid 40361316)
133. Araujo AB, Travison TG, Harris SS, et al. Race/ethnic differences in bone mineral density in men. Osteoporos Int 2007 ; 18 : 943-953 (Pubitemid 46889553)
134. Als OS, Gotfredsen A, Christiansen C. The effect of glucocorticoids on bone mass in rheumatoid arthritis patients. Infl uence of menopausal state. Arthritis Rheum 1985 ; 28 : 369-375
135. Rizzoli R, Bonjour JP, Ferrari SL. Osteoporosis, genetics and hormones. J Mol Endocrinol 2001 ; 26 : 79-94 (Pubitemid 32266184)
136. Van Staa TP, Leufkens HG, Cooper C. Utility of medical and drug history in fracture risk prediction among men and women. Bone 2002 ; 31 : 508-514 (Pubitemid 35189541)
137. Thompson JM, Modin GW, Arnaud CD, Lane NE. Not all postmenopausal women on chronic steroid and estrogen treatment are osteoporotic: predictors of bone mineral density. Calcif Tissue Int 1997 ; 61 : 377-381 (Pubitemid 27507902)
138. Law MR, Hackshaw AK. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. BMJ 1997 ; 315 : 841-846 (Pubitemid 27420442)
139. Joakimsen RM, Magnus JH, Fonnebo V. Physical activity and predisposition for hip fractures: a review. Osteoporos Int 1997 ; 7 : 503-513 (Pubitemid 28009010)
140. Baltzan MA, Suissa S, Bauer DC, Cummings SR. Hip fractures attributable to corticosteroid use. Study of Osteoporotic Fractures Group. Lancet 1999 ; 353 : 1327 (Pubitemid 29178787)
141. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998 ; 339 : 292-299
142. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001 ; 44 : 202-211 (Pubitemid 32113136)
143. Frediani B, Falsetti P, Baldi F, et al. Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound. Bone 2003 ; 33 : 575-581 (Pubitemid 37229075)
144. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997 ; 337 : 382-387 (Pubitemid 27328368)
145. Roux C, Oriente P, Laan R, et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. J Clin Endocrinol Metab 1998 ; 83 : 1128-1133 (Pubitemid 28496380)
146. Eastell R, Devogelaer JP, Peel NF, et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 2000 ; 11 : 331-337 (Pubitemid 30417186)
147. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999 ; 42 : 2309-2318 (Pubitemid 30333410)
148. Reid DM, Hughes RA, Laan RF, et al. Effi cacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000 ; 15 : 1006-1013